Key Takeaways
- Tesamorelin and Sermorelin are both growth hormone-releasing hormone (GHRH) analogs. They signal your pituitary gland to release your own growth hormone rather than replace it.
- Tesamorelin is FDA-approved (as Egrifta SV and Egrifta WR) for one use: reducing excess abdominal fat in adults with HIV-associated lipodystrophy. Its label states it is not a weight-loss drug.
- Sermorelin was FDA-approved as Geref for children, then its manufacturer discontinued it in 2008 for reasons the FDA later confirmed were not safety-related. Adult use today is compounded and off-label.
- Tesamorelin was tested in two phase 3 trials of 412 and 404 adults with HIV. Sermorelin's adult evidence comes from small trials of injected GHRH analogs in older adults.
- Both raise IGF-1, the main blood marker of the growth hormone axis. Tesamorelin's label requires IGF-1 and blood glucose monitoring.
- Tesamorelin comes as an injection only. Compounded Sermorelin is also prescribed as a nasal spray or a sublingual troche.
Tesamorelin is FDA-approved for one HIV-related use and backed by two phase 3 trials. Sermorelin is compounded and prescribed off-label for adult sleep and recovery goals.
Both act on the GH/IGF-1 axis: growth hormone (GH) from the pituitary prompts the liver to make insulin-like growth factor 1 (IGF-1), the marker clinicians use to track that axis. If you're weighing Tesamorelin vs Sermorelin for energy, sleep, or recovery rather than an HIV-related diagnosis, the question is whether prescription Sermorelin fits your health history, and in which format.
Sermorelin vs Tesamorelin at a glance
| Feature | Sermorelin | Tesamorelin |
|---|---|---|
| What it is | The first 29 amino acids of GHRH, the shortest active fragment | Full 44-amino-acid GHRH with a stabilizing chemical group added |
| FDA status | Formerly approved as Geref; now compounded, not FDA approved | Approved (Egrifta SV, Egrifta WR) |
| Approved use | None currently; historically pediatric growth hormone deficiency and pituitary testing | Excess abdominal fat in adults with HIV-associated lipodystrophy |
| Strongest human evidence | A 16-week trial of an injected GHRH analog in 19 adults aged 55 to 71 | Two phase 3 trials in 412 and 404 adults with HIV |
| Stability | Unmodified 29-amino-acid fragment | Chemically stabilized; plasma half-life about 8 minutes (FDA label) |
| Formats | Injection, nasal spray, or sublingual troche (compounded) | Injection |
| Monitoring | Set by the prescribing clinician; no FDA-labeled monitoring schedule | IGF-1 and glucose monitoring called for on the label |
| Sport | Prohibited by WADA | Prohibited by WADA |
How Sermorelin and Tesamorelin work
Both bind the same receptor on the pituitary. They differ in structure: Tesamorelin is the full 44-amino-acid chain with a stabilizing group, and Sermorelin is the first 29 amino acids.
Same receptor, different structure
Both peptides bind to the GHRH receptor on pituitary somatotroph cells, triggering a pulse of endogenous growth hormone. That GH then stimulates IGF-1 production in the liver.
Tesamorelin's FDA label describes it as the full 44-amino-acid GHRH chain with a hexenoyl group attached, a change made to keep it more stable than native GHRH. Its plasma half-life is still short, about 8 minutes. Sermorelin has no such modification.
How the formats differ
Tesamorelin comes only as an injection. In its phase 3 trials, Tesamorelin raised IGF-1 by about 107 ng/mL over 26 weeks. Sermorelin comes as an injection, a nasal spray, or a sublingual troche. Strengths differ by format (3 mg/mL for the injection, 1 mg/mL for the nasal spray, and 1 mg per troche) and cannot be converted one-for-one. Your clinician sets how you use it, and your prescription label carries those directions.
How both differ from HGH
Somatropin is synthetic human growth hormone itself. It supplies GH from outside and bypasses the pituitary. Tesamorelin and Sermorelin rely on a working pituitary. For that reason, Tesamorelin's label rules it out after pituitary surgery, head irradiation, or head trauma.
Tesamorelin and Sermorelin FDA approval status
One is an approved brand-name drug for a narrow indication. The other is a formerly approved molecule now available only through compounding pharmacies.
Tesamorelin: Egrifta SV and Egrifta WR
Tesamorelin is FDA-approved for reducing excess abdominal fat in HIV-infected adults with lipodystrophy. The Egrifta SV prescribing information lists two limits: long-term cardiovascular safety has not been established, and it is not indicated for weight loss because its effect on body weight is neutral. Any use outside the HIV indication is off-label.
Sermorelin: approved, discontinued, now compounded
Sermorelin was approved as Geref in two forms: a 1990 diagnostic for testing pituitary GH release and a 1997 treatment for idiopathic growth hormone deficiency in children. EMD Serono discontinued both in 2008, and the FDA withdrew the approvals in 2009. In 2013, a Federal Register determination confirmed Geref was not withdrawn for reasons of safety or effectiveness.
What compounded and off-label mean
Adult Sermorelin today is prepared by licensed compounding pharmacies against an individual prescription. At Rebody, a licensed U.S. 503A compounding pharmacy fills each prescription only after a clinician reviews it. There is no FDA-reviewed adult label, so your prescriber sets the dose, the schedule, and the follow-up labs.
What the evidence shows for each peptide
Tesamorelin's evidence base is the stronger of the two.
Tesamorelin: large trials in one population
- The first phase 3 trial randomized 412 HIV-positive adults with excess abdominal fat to Tesamorelin or placebo for 26 weeks. Visceral fat fell 15.2% on Tesamorelin and rose 5.0% on placebo, and triglycerides dropped by about 50 mg/dL.
- In the confirmatory 404-patient trial, visceral fat fell 10.9% at 6 months versus 0.6% on placebo, and about 18% in people who stayed on Tesamorelin for 12 months.
- In the 52-week extension study, people who switched from Tesamorelin to placebo at week 26 regained nearly all the visceral fat they had lost by week 52. The effect depends on continued use.
None of these trials studied healthy adults pursuing energy, sleep, or longevity goals.
Sermorelin: smaller studies, mostly older adults
Sermorelin's adult evidence is thinner. A 16-week trial in 19 adults aged 55 to 71 used injections of a close GHRH(1-29) analog. It raised nocturnal GH and IGF-1 within two weeks, though IGF-1 drifted back toward baseline by week 16.
Sleep research on GHRH is mixed: it deepened sleep in men but disrupts sleep in women. Your provider can track how your sleep responds over the first few months. No published trial has tested the finished nasal spray or troche, so evidence for those methods is thinner than for injection.
Has Tesamorelin ever been compared with Sermorelin?
We found no published trial comparing Tesamorelin and Sermorelin directly. Any claim that one "works better" for general wellness goals is an inference from different populations, doses, and methods.
Side effects and safety
The Tesamorelin label reports side-effect rates from its trials. Sermorelin has no current FDA label, so its side-effect list comes from compounding-pharmacy product information.
Tesamorelin risks
The main concerns with Tesamorelin center on glucose metabolism and IGF-1 elevation. From the Tesamorelin prescribing information:
- IGF-1 elevation: after 26 weeks, 47% of patients had IGF-1 above 2 standard deviation scores. The label calls for IGF-1 monitoring.
- Glucose intolerance: 5% of Tesamorelin patients reached an HbA1c of 6.5% or higher by week 26, versus 1% on placebo. The label calls for a glucose check before starting and at intervals during treatment.
- Skin reactions where the injection is given: 25% on Tesamorelin versus 14% on placebo in the first 26 weeks.
- Fluid retention: swelling, joint pain, and carpal tunnel symptoms, which go away on their own or after stopping, per the label.
- Contraindications: pregnancy, active malignancy, known hypersensitivity, and a disrupted hypothalamic-pituitary axis (for example, after pituitary surgery, head irradiation, or head trauma).
Sermorelin risks
Pharmacy product information for compounded Sermorelin lists pain or redness where the injection is given, headache, flushing, dizziness, nausea, and sleepiness. The nasal spray adds nasal irritation and a runny nose; the troche adds mouth or tongue irritation and an unusual taste.
Tell your clinician about any history of diabetes, and report unusual thirst or frequent urination, which can signal high blood sugar. Sermorelin is not prescribed during pregnancy or breastfeeding, with active or past cancer, or to anyone under 18.
For tested athletes
The World Anti-Doping Agency prohibits GHRH and its analogs at all times, and its 2026 Prohibited List names both Sermorelin and Tesamorelin under category S2.
Which is better: Tesamorelin or Sermorelin?
The right choice depends on your diagnosis and goal.
- Tesamorelin fits an adult with HIV-associated lipodystrophy who needs an FDA-approved option with a defined label and label-based monitoring.
- Sermorelin fits an adult without that diagnosis who wants clinician-guided GH-axis support for sleep, recovery, or energy, accepts a smaller evidence base, and wants a choice of formats.
Outside the HIV indication, any Tesamorelin use is off-label. Sermorelin is prescribed through compounding pharmacies in three methods: injection, nasal spray, and sublingual troche.
What a clinician reviews
- Your goal: a diagnosed condition, or sleep, recovery, and energy.
- Your health history and medications, including diabetes, cancer, pituitary disease, and pregnancy.
- Baseline IGF-1 and blood glucose (fasting glucose or HbA1c).
- The method you will keep using: injection, nasal spray, or troche.
- A follow-up at about three months to compare labs, symptoms, and side effects.
Rebody's clinicians prescribe Sermorelin in three formats, not only as an injection. A Sermorelin sublingual troche (1 mg) is needle-free, and a Sermorelin nasal spray takes seconds with no syringe.
Sermorelin's strongest human data come from injections, and no published study has measured how much Sermorelin the troche or spray delivers compared with an injection, so work with your provider to track how you respond over time, including bloodwork. See how the three Sermorelin formats compare for storage, convenience, and evidence by format.
Which peptide is better for someone on TRT?
Neither peptide has been studied in controlled trials as an add-on to testosterone replacement therapy (TRT). Tesamorelin fits if you also have HIV-associated lipodystrophy, and any other use is off-label. Sermorelin is prescribed off-label for sleep, recovery, and energy goals.
If you're on TRT, share your testosterone prescription and recent labs with your clinician before starting either peptide, so they can track IGF-1 and blood glucose alongside your testosterone levels.
For men who would rather raise their own testosterone than take TRT, enclomiphene is an oral option that works through the body's LH and FSH signal and starts with bloodwork.
Can you take Tesamorelin and Sermorelin together?
There's no evidence to support it. No published trial has tested the two together, and Tesamorelin's prescribing information doesn't cover combining it with another GHRH analog.
Both peptides bind the same GHRH receptor on the pituitary, so pairing them doesn't add a second mechanism the way some peptide combinations do. Tesamorelin's label already calls for IGF-1 and blood glucose monitoring, and no study has measured either marker with both peptides in use.
If you're on one and curious about the other, talk to your clinician before changing anything. They can review your labs and decide whether switching makes more sense than adding.
Alternatives to Tesamorelin and Sermorelin
Other options act on the same axis, with very different regulatory status.
| Option | What it is | FDA status | Evidence note |
|---|---|---|---|
| Somatropin | Recombinant human growth hormone | Approved for diagnosed adult GH deficiency | Replaces GH directly; requires a confirmed diagnosis |
| CJC-1295 | Long-acting GHRH analog | Not approved; FDA cites increased heart rate and vasodilatory reactions | In 12 healthy men, a single injection raised mean GH 46% and IGF-1 about 45% a week later |
| Ipamorelin | Ghrelin-receptor agonist (GHRP) | Not approved; on FDA's compounding safety-risk list | Limited human safety data |
| Ibutamoren (MK-677) | Oral GH secretagogue | Not approved; FDA cites a possible heart failure signal from a hip-fracture trial | In a trial of 65 adults aged 60 to 81, it raised GH and IGF-1 and added fat-free mass without improving physical function |
For a closer look at the ghrelin-receptor option, see Ipamorelin vs Sermorelin.
Choosing a growth hormone peptide with a clinician
Tesamorelin has stronger evidence, FDA approval for one HIV-related use, and larger documented IGF-1 increases, with label-required IGF-1 and glucose monitoring.
Sermorelin is prescribed off-label for adults without that diagnosis and comes as an injection, nasal spray, or sublingual troche. A licensed provider reviews your goals, history, and labs, a licensed U.S. 503A pharmacy prepares the format you choose, and your care team follows up as your labs and symptoms change.
Schedule a consult with a Rebody clinician to see whether Sermorelin fits your goals and health history, and which format fits you.
Frequently Asked Questions (FAQs)
Is Tesamorelin FDA-approved?
Yes. Tesamorelin is approved as Egrifta SV and Egrifta WR to reduce excess abdominal fat in adults with HIV-associated lipodystrophy. Use for any other purpose is off-label, and the label states it is not a weight-loss drug.
Is Sermorelin FDA approved?
Not currently. Sermorelin was approved as Geref for children with growth hormone deficiency, but the manufacturer discontinued it in 2008. Sermorelin prescribed to adults today is compounded and not FDA-approved.
Can you take Tesamorelin and Sermorelin together?
There's no evidence to support it. No published trial or FDA label covers combining them, and both act on the same GHRH receptor. Any change needs a clinician to review your IGF-1 and blood glucose.
Does Tesamorelin make you stronger?
Tesamorelin's trials did not measure strength. In its two phase 3 trials, lean body mass rose 1.2 to 1.3 kg over 26 weeks in adults with HIV-associated lipodystrophy.
Does Tesamorelin come as a nasal spray or troche?
No. Tesamorelin comes only as an injection, under the Egrifta SV and Egrifta WR brands. Compounded Sermorelin is also prescribed as a nasal spray or a sublingual troche.
Which growth hormone peptide is the strongest?
Tesamorelin has the most trial data: it raised IGF-1 by about 107 ng/mL over 26 weeks. No trial has compared it head-to-head with Sermorelin or other growth hormone peptides.
Can Sermorelin help raise testosterone levels?
No. Sermorelin signals growth hormone release, not testosterone, and it is not prescribed to raise testosterone. For men who want to raise their own testosterone, a clinician may prescribe enclomiphene, an oral medication that prompts the pituitary to release LH and FSH, the hormones that signal the testes to make testosterone. Treatment starts with blood tests to confirm low testosterone.
Are Tesamorelin and Sermorelin banned in sports?
Yes. The World Anti-Doping Agency prohibits growth hormone-releasing hormone and its analogs at all times, and its list names both peptides. Athletes with a documented medical need can apply for a Therapeutic Use Exemption.
This article is for informational purposes only and does not provide medical advice, diagnosis, or treatment. Consult a qualified healthcare professional about your health or before changing treatment. Do not delay medical care because of something you read here.